Brera Holdings PLC (BREA) Expands Commitment to Women’s Football and Multi-Club Ownership (‘MCO’) Model

Clene Inc.’s (CLNN) CNM-Au8(R) Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

D-Wave Quantum Inc. (QBTS) Demonstrates Quantum Suprzemacy on a Real-World Problem

Adageis on Track to Exceed Q1 Growth Target, Expanding Healthcare AI Platform

Thumzup Media Corp. (TZUP) Boosts Shareholder Value with Share Buyback

Allos Therapeutics, Inc. (NASDAQ: ALTH)

November 3, 2008 at 4:03am

Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company, is committed to developing and commercializing innovative small molecule drugs for the treatment of cancer. Pralatrexate (PDX), the Company’s lead product candidate, is a novel antifolate currently in a pivotal Phase 2 (PROPEL) trial. RH1, a targeted chemotherapeutic agent, is Allos Therapeutics’ other product candidate and is currently being evaluated in a Phase 1 trial. For further information, visit the Company’s web site at www.allos.com.

Archives

Select A Month

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.